tDCS Plus Varenicline for Smoking Cessation
Key facts
- Who runs it
- Centre for Addiction and Mental Health
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 160 people, planned
- Started
- 10 Mar 2025
- Expected to end
- 1 Aug 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Active Transcranial Direct Current Stimulation (tDCS)
- Varenicline 1mg BID
- Sham Transcranial Direct Current Stimulation (tDCS)
- Record updated
- 12 August 2025
Who can take part
- Age
- 18 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Be able to provide informed written consent
- Stated willingness to comply with all study procedures
- Age 18-85 years
- Smoke ≥ 8 cigarettes per day (CPD)
- Is seeking treatment for tobacco dependence
- Willing to attend the required clinic appointments (Two consecutive weeks, Monday through Friday)
- Otherwise healthy (i.e. not suffering from any major illness/condition that would impact their participation in the study)
Who cannot take part
- Use of smoking cessation medication (e.g. buproprion, varenicline, NRT, cytisine) in the past 3 months
- Unstable psychiatric illness that would adversely impact study participation and compliance (determined by the QI)
- History of seizures/epilepsy
- Lifetime history of concussions or head traumas
- Contraindications to varenicline use (e.g. pregnant/breastfeeding, alcohol dependence, kidney disease/renal impairment, known hypersensitivity to varenicline)
- Current regular use of nicotine-containing products besides cigarettes (e.g. electronic cigarettes, etc.)
- Current pregnancy or plans to become pregnant
- Current pacemakers or implanted electrical devices
- Current metal embedded in the skull
- Presence of skin lesions, open wounds, or bruising at stimulation sites; or
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to determine if active transcranial direct current stimulation (tDCS) plus varenicline is an effective, safe and accessible treatment option for smoking cessation. The main questions this trial aims to answer are:
Read full original descriptionShow less
1. Does active tDCS plus varenicline improve short-term and long-term smoking abstinence rates compared to sham tDCS plus varenicline? 2. Are the safety profiles between active tDCS plus varenicline and sham tDCS plus varenicline different?
The tDCS treatment schedule includes 10 daily sessions for the first 2 weeks (M to F), followed by 5 single bi-weekly booster sessions for the remainder of the treatment period. Participants will come in-person for two follow-up sessions to assess smoking behaviour at 6- and 12-months post-treatment.
The 2 groups in the trial
- Experimental Group (Active tDCS plus Varenicline)Existing treatment, for comparison
The experimental group will receive active tDCS sessions plus 12 weeks of 1 mg varenicline bid. Participants will start varenicline treatment on the same day as the first tDCS session, and will follow a standard dose escalation schedule. The tDCS treatment schedule includes 10 daily sessions for the first 2 weeks (M to F), followed by 5 single bi-weekly booster sessions for the remainder of the treatment period. Participants will come in-person for two follow-up sessions to assess smoking behaviour at 6- and 12-months post-treatment.
Treatment: Active Transcranial Direct Current Stimulation (tDCS) and Varenicline 1mg BID
- Control GroupSham treatment, for comparison
The control group will receive sham (fake) tDCS sessions plus 12 weeks of 1 mg varenicline bid. Participants will start varenicline treatment on the same day as the first tDCS session, and will follow a standard dose escalation schedule. The tDCS treatment schedule includes 10 daily sessions for the first 2 weeks (M to F), followed by 5 single bi-weekly booster sessions for the remainder of the treatment period. Participants will come in-person for two follow-up sessions to assess smoking behaviour at 6- and 12-months post-treatment.
Treatment: Varenicline 1mg BID and Sham Transcranial Direct Current Stimulation (tDCS)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Using Non-Invasive Brain Stimulation (tDCS) as an Adjunct to Varenicline for the Treatment of Tobacco Dependence: a Randomized Controlled Trial
- Fit questions
- Built from NCT06798324, who can take part
- Record updated
- 12 August 2025